# Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas

> **NCT02495415** · PHASE2 · UNKNOWN · sponsor: **CerRx, Inc.** · enrollment: 140 (estimated)

## Conditions studied

- Peripheral T-cell Lymphoma

## Interventions

- **DRUG:** Fenretinide

## Key facts

- **NCT ID:** NCT02495415
- **Lead sponsor:** CerRx, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-12
- **Primary completion:** 2021-07
- **Final completion:** 2021-12
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2019-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02495415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02495415, "Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02495415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*